ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Interferon beta-1a

Also written as “Rebif®”, “RNF” and “Rebif”.

Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.

Drug pageInterferon beta-1a: every studyMany companies study it; this page follows only the 53 they lead. All 82 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 200553 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogenits history only230 open or runningphase 4since Sep 13, 2005Dec 15, 2004none ahead
Merck KGaA, Darmstadt, Germanyits history only210 open or runningphase 4since Feb 23, 2004Feb 23, 2004none ahead
Faron Pharmaceuticalsits history only30 open or runningphase 3since Nov 24, 2015Nov 24, 2015none ahead
Biocadits history only20 open or runningphase 3since May 29, 2015Jan 10, 2013none ahead
Cinnagen20 open or runningphase 3since Jan 17, 2022Jul 14, 2018none ahead
Azidus Brasilits history only10 open or runningphase 1since Nov 13, 2009Nov 13, 2009none ahead
Trio Medicinesits history only10 open or runningphase 1since May 20, 2013May 20, 2013none ahead

Also a collaborator on its studies: Toray Industries, Pfizer, Gesellschaft für Therapieforschung mbH, Merck Serono S.P.A., Italy, Merck Serono S.A.S, France, EMD Serono Canada, Elan Pharmaceuticals, Merck Pte. Ltd., Singapore and Merck Serono International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Cinnagen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 14, 2018First study: phase 1 study in BioequivalenceFirst studyNCT03614715 · 40 enrolled · Finland
  2. Jan 17, 2022Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT05242133 · 168 enrolled · Iran, Islamic Republic of

TargetBeta

“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Studies

All 2 Cinnagen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05242133Multiple Sclerosis, Relapsing-Remitting · Iran, Islamic Republic of3CompletedApr 27, 2022168
NCT03614715Bioequivalence · Finland1CompletedFeb 12, 201940

How it is read

Names in the registry

  • “Interferon beta-1a”, 11 entries
  • “Rebif®”, 7 entries
  • “RNF”, 5 entries
  • “Rebif”, 4 entries
  • “SNG001”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.